United Therapeutics (UTHR) FCF Margin (2009 - 2026)

United Therapeutics has disclosed FCF Margin across 18 years of filings, most recently posting 46.39% for Q1 2026.

• FCF Margin for Q1 2026 came in at 46.39%, down 573.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 43.96% (down 166.0% YoY), and the FY2025 annual result was 45.4%, up 5.0% from the prior year.
• FCF Margin came in at 46.39% for Q1 2026 at United Therapeutics, up from 40.76% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 75.92% in Q3 2025 to a low of 10.33% in Q2 2023.
• The 5-year median for FCF Margin is 40.76% (2025), against an average of 40.09%.
• Across the five-year window, FCF Margin soared 5335 bps in 2024 and plunged 2430 bps in 2025, its largest moves.
• United Therapeutics' FCF Margin stood at 18.05% in 2022, then sank by 35 bps to 11.71% in 2023, then surged by 455 bps to 65.06% in 2024, then plunged by 37 bps to 40.76% in 2025, then climbed by 14 bps to 46.39% in 2026.
• The last three FCF Margin figures came in at 46.39% (Q1 2026), 40.76% (Q4 2025), and 75.92% (Q3 2025), per Business Quant data.